Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
J R Falck)
Cancer Research. 2014;74(2):621-631.Abstract
Non-small cell lung cancer (NSCLC) not amenable to surgical resection has a high mortality rate, due to the ineffectiveness and toxicity of chemotherapy. Thus, there remains an urgent need of efficacious drugs that can combat this disease. In this study, we show that targeting the formation of proangiogenic epoxyeicosatrienoic acids (EET) by the cytochrome P450 arachidonic acid epoxygenases (Cyp2c) represents a new and safe mechanism to treat NSCLC growth and progression. In the transgenic murine K-Ras model and human orthotopic models of NSCLC, we found that Cyp2c44 could be downregulated by activating the transcription factor PPARa with the ligands bezafibrate and Wyeth-14,643. Notably, both treatments reduced primary and metastatic NSCLC growth, tumor angiogenesis, endothelial Cyp2c44 expression, and circulating EET levels. These beneficial effects were independent of the time of administration, whether before or after the onset of primary NSCLC, and they persisted after drug withdrawal, suggesting the benefits were durable. Our findings suggest that strategies to downregulate Cyp2c expression and/or its enzymatic activity may provide a safer and effective strategy to treat NSCLC. Moreover, as bezafibrate is a well-tolerated clinically approved drug used for managing lipidemia, our findings provide an immediate cue for clinical studies to evaluate the utility of PPARa ligands as safe agents for the treatment of lung cancer in humans. © 2013 American Association for Cancer Research.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Wei Yu; Li Chen; Yu-Qing Yang; John R. Falck; Austin M. Guo; Ying Li; Jing YangCancer Chemotherapy and Pharmacology. 2011;68(3):619-629.
Santanu Dasgupta; Jin Sung Jang; Chunbo Shao; Nitai D Mukhopadhyay; Upneet K Sokhi; Swadesh K Das; Mariana Brait; Conover Talbot; Rex C Yung; Shahnaz Begum; et al.Journal of molecular medicine (Berlin, Germany). 2013;91(3):381-393.
Monica Spinola; Felicia S. Falvella; Francesca Colombo; James P. Sullivan; David S. Shames; Luc Girard; Paola Spessotto; John D. Minna; Tommaso A. DraganiMolecular Cancer. 2010;9.
Appears in this Document